English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, April 23, 2021
エーザイ、アデュカヌマブのブラジル・カナダ・オーストラリア・スイスにおける販売承認申請の提出について
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
Tuesday, April 20, 2021
エーザイ、Lecanemab(BAN2401)の早期アルツハイマー病に対する18カ月の臨床第IIb相試験の結果が査読学術専門誌Alzheimer's Research and Therapy誌に掲載
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
Wednesday, April 14, 2021
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
エーザイ、米国神経学会年次総会にて神経領域の開発品・製品に関する最新データを発表
Monday, April 12, 2021
エーザイ、リンパ系フィラリア症の制圧活動に関するアニメーション動画がInternational Society for Neglected Tropical Diseasesフェスティバルアワード2021で「アニメーション賞」を受賞
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
Wednesday, March 31, 2021
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575